Pharmacyclics Inc

Pharmacyclics — Technical Presentation (June 2014)

18 slides from Pharmacyclics's technical presentation, Jun 5, 2014

  1. Slide 1: Randomized Comparison of Ibrutinib Versus Ofatumumab in Relapsed or Refractory CLL/SLL: RESONATE Trial

    Randomized Comparison of Ibrutinib Versus Ofatumumab in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Results From the Phase III RESONATE™ Trial John. Byrd Jennifer R. Brown,? Susan O'Brien,? Jacqueline C. Barrientos,’ Neil. Kay,° Nishitha M. Reddy,* Steven Coutre,’

  2. Slide 2: Background

    Background Patients with CLL and SLL who experience a short response duration to initial therapy, who are elderly (age >65 years) or have del(17p) have poor outcomes and limited treatment options!* Ibrutinib is a first-in-class, once-daily, orally administered covalent inhibitor of Bruton’s tyrosine

  3. Slide 3: RESONATE Phase 3 Study Design

    RESONATE™ Phase 3 Study Design Oral ibrutinib 420mg once Enrollment Dates: daily until PD or unacceptable June 2012 April 2013 toxicity Patients with iM 1-195, previously #2) treated Q) cus Wofatumumab initial dose of Crossover to ibrutiib 300 mg followed by 2000 mg 420mg once daily after | Z x11 do

  4. Slide 4: Study Objectives

    Study Objectives ™ Primary Objective — PFS as assessed by the IRC per 2008 IWCLL criteria! with the 2012 clarification for treatment-related lymphocytosis? ™ Secondary Objectives — Overall survival — IRC-assessed overall response rate® — Safety and tolerability " Exploratory Objective — Investigator

  5. Slide 5: Inclusion Criteria

    Inclusion Criteria ® Diagnosis of CLL/SLL that met published diagnostic criteria? ® >I prior therapy ® Considered inappropriate for treatment/retreatment with purine analogs due to: — Ashort progression free interval (<3 years) following combination chemoimmunotherapy — Advanced age (70 or older, or

  6. Slide 6: Patient Disposition

    Patient Disposition Ibrutinib Ofatumumab Study treatment phase disposition (N=195), % (N=196),% Did not receive study drug 0 Discontinued or completed 14 97 Completion of planned treatment regimen? 61 Ongoing 86 1 Median time on study at time of analysis, 9.6 (0.33-16.62) 9,2 (0.07-16.49) mos (range

  7. Slide 7: Baseline Characteristics

    Baseline Characteristics Ibrutinib fatumumab (N=195) (Nv=196) CLY/SLL,% 9 96/4 Median age (range), years 67(30-86) 67(37-88) Male, % 66 70 Refractory to purine analogs,°% 45 4 ECOG PS 1,% 59 59 Raistagell/IV,% 56 58 | Bulky disease 25 cm, % 64 32 Deldlg% 2 30 | Dell7p,% 32 33 Median (range) prior Rx

  8. Slide 8: Progression-Free Survival

    Progression-Free Survival 2 ‘Median time (mo) 8,08 NR Hazardratio 0.215 (osc) (ait60317) ‘log-rank P value < 0.0001 WR, not reached. Progression-Free Survival (26) s 2 — Ibrutinib ++ Ofatumumab 4 3 6 3 2 5 Months \brutinib significantly prolonged PFS; median not reached vs. 8.1 months for ofatumumab

  9. Slide 9: Progression-Free Survival by Baseline Characteristics and Molecular Features

    Progression-Free Survival by Baseline Characteristics and Molecular Features Favors: iwor Harard ibrutin ofatumumab ratio __95%Cl Asubjects EE 3a oat (014031) fefactoy disease to purine analogs, Yes | —*—= | 175 0.48 (010-032) No = + 26 0.24 (0.15-0.40) Delt7p, Yes i= | 17 0.25 (044-045) No a= + 264

  10. Slide 10: Overall Survival

    Overall Survival 10 a — Ihrutni (n=195, 16 events) += Ofatumumab (n=196, 33 events) i gn 5 Ofatumumab Ibrutinib ge ‘Median time (mo) NR MR 3 4- Hazardratio 0.434 5 (95%) (0238-0785) 3" LogankPvalue 0.0089 0 a 10 See 0 a 6 9 nN a) 18 Month ® [brutinib significantly prolonged 0S compared with ofatumum

  11. Slide 11: Overall Response to Therapy: IRC and Investigator Assessment

    Overall Response to Therapy: IRC and Investigator Assessment 100 100 IRCAssessment Investigator Assessment i, 80 18% 80> by 63% 0 60 20% 54% 40 40 32% 16.23% 0 o) w 14% 10% 1% x» a 1% 1 pref ea oR r Ry pe SD PD PR SD PD pri SD PD paul SD PD roo ro {bratinib Ofatumumab Ibratinib Ofatumumab (N=195) (N

  12. Slide 12: Best IRC Response without Second CT Confirmation

    Best IRC Response without Second CT n . Confirmation Ibrutinil Ofatumumal Best overall response? % (95% Cl) ITT (n=195, 196) 76% (69%-82%) 11% (7%-16%) Evaluable (n=190, 181)* 78% (71%-84%4) 12% (7H-17%) 50% reduction in lymph nodes?, % (95% Cl) (n=190, 174)* Organomegaly response, % 92% (89%-96%) 1

  13. Slide 13: Safety: Adverse Events (≥15%) Regardless of Attribution

    Safety: Adverse Events (215%) Regardless of Attribution? Ibrutinih Ofatumumab (N=195) (N=191) Anygrade Grade3/4 Anygrade Grade3/4 |Any TEAE, % 99 51 98 39 Diarrhea 4 4 18 2 Fatigue 28 2 30 z Nausea 6 2 18 0 | Pyrexia 4 i! sty 1 Anemia B 5 7 8 Neutropenia 2 16 b 14 Cough 19 0 3B 1 Thrombocytopenia 7

  14. Slide 14: Safety Overview

    Safety Overview Ibrutiniby Ofatumumab Adverse event, % (N=195) (N=191) |Sbjetsreponting 2 SAS a 30 | Reporting 21 AE grade 23 37 47 Any infection grade 23 4 n Grade 23 AE atrial fibrillation 3 0 | ‘Major hemorrhage” a 2 rate increase or any grade 23 A for rutii compared “posure adjusted analysis did

  15. Slide 15: Safety: Atrial Fibrillation and Bleeding-Related Adverse Events

    Safety: Atrial Fibrillation and Bleeding-Related Adverse Events ® Atrial fibrillation of any grade, was noted more frequently in patients receiving ibrutinib (n=10) compared with ofatumumab (n=1) = Led to discontinuation of ibrutinib in only 1 patient; patients were 260 years old (median age 73); mo

  16. Slide 16: Conclusions

    ® |brutinib significantly improves PFS, OS, and response as compared with ofatumumab ® The impact of ibrutinib on PFS was observed irrespective of baseline clinical characteristics or molecular features including the high-risk del17p and purine-refractory subgroups ™ Investigator assessed PFS is con

  17. Slide 17: Acknowledgments

    Acknowledgments ™ The patients and their families, without whose support this trial would not have been possible ™ The independent data monitoring committee ™ The independent review committee ® The many employees at Pharmacyclics who coordinated this trial and the support companies that worked with

  18. Slide 18: Acknowledgments

    Acknowledgments "The investigators®, study coordinators, study team, and nurses who treated the patients Peter Hillmen, Jennifer Brown, Susan O'Brien, Jacqueline Barrientos, Neil Kay, Nishitha Reddy, Steven Coutre, Constantine Tam, Stephen Mulligan, Ulrich Jaeger, Steve Devereux, Paul Barr, Richard

Pharmacyclics — Technical Presentation (June 2014) on 6ix